Kranti Industries manufactures high-precision machined components such as differential housings, axle parts, and transmission components for major vehicle and equipment manufacturers in the tractor, automotive, and construction sectors.
The company operates in a highly competitive, capital-intensive precision engineering market where it lacks a clear moat mechanism like high switching costs or brand power. While it has long-term relationships with OEMs, its low average net margins (0.5%) and ROCE (7.0%) indicate a lack of pricing power and a commodity-like business profile.
Management has aggressively reinvested in capacity expansion, including a new plant in Jaipur and a joint venture in Gujarat, but these investments have yet to translate into high returns on capital, with ROE averaging only 2.5%.
The company's aggressive capacity expansion into Jaipur and Gujarat, funded by high-cost debt and dilutive share issuances, failed to generate returns above its cost of capital. As the cyclical tractor segment entered a prolonged downturn, the razor-thin 0.5% net margins evaporated into persistent losses. With interest coverage already at a precarious 1.5x, the debt burden became unsustainable, forcing the business into a spiral of working capital shortages and further equity dilution that gutted shareholder value.
RichFakir rates Kranti Industries Ltd's business quality as poor — 19/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Kranti Industries Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Kranti Industries Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Kranti Industries Ltd's fair value is about ₹10 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →